Each year about 90,000 men seek treatment for recurrent prostate cancer, and evaluating them for recurrence is a major challenge. Physicians have to wait until a patient’s prostate-specific antigen (PSA) levels rise to a certain level to identify sites of the recurrence.
Now Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C-11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer.
Click here for news release
Expert titles for broadcast cg:
Dr. Eugene Kwon, Mayo Clinic Urologist
Dr. Val Lowe, Mayo Clinic Radiologist